DE3176491D1
(en)
*
|
1980-03-05 |
1987-11-26 |
Miles Lab |
Pasteurized therapeutically active protein compositions
|
JPS56135418A
(en)
*
|
1980-03-27 |
1981-10-22 |
Green Cross Corp:The |
Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
|
US4305871A
(en)
*
|
1980-09-02 |
1981-12-15 |
Edward Shanbrom |
Method of selectively increasing yield and purity of certain cryoprecipitate proteins by heating
|
DE3043857A1
(de)
*
|
1980-11-21 |
1982-07-08 |
Behringwerke Ag, 3550 Marburg |
Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
|
DE3045153A1
(de)
*
|
1980-11-29 |
1982-07-08 |
Behringwerke Ag, 3550 Marburg |
Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x
|
IT1194135B
(it)
*
|
1981-01-05 |
1988-09-14 |
Novo Industri As |
Composizioni di plasmina stabilizzata e metodo per la loro preparazione
|
JPS57140724A
(en)
*
|
1981-02-25 |
1982-08-31 |
Green Cross Corp:The |
Heat-treatment of aqueous solution containing cold insoluble globulin
|
US4480029A
(en)
*
|
1981-04-27 |
1984-10-30 |
Baxter Travenol Laboratories, Inc. |
Biological indicators and their use
|
US4495278A
(en)
*
|
1981-04-27 |
1985-01-22 |
Baxter Travenol Laboratories, Inc. |
Process for making novel blood clotting enzyme compositions
|
EP0286198B1
(en)
*
|
1981-04-27 |
1994-12-14 |
BAXTER INTERNATIONAL INC. (a Delaware corporation) |
Blood clotting enzyme compositions
|
DE3119157A1
(de)
*
|
1981-05-14 |
1982-12-09 |
Behringwerke Ag, 3550 Marburg |
Verfahren zur herstellung von und danach hergestelltes plasminogen
|
EP0081482A1
(en)
*
|
1981-06-18 |
1983-06-22 |
E. G. Birger Blombäck |
A process in purification and concentration of the factor viii complex
|
JPS5874617A
(ja)
*
|
1981-10-28 |
1983-05-06 |
Green Cross Corp:The |
人由来血液凝固第7因子含有水溶液の加熱処理方法
|
US4845074A
(en)
*
|
1982-05-13 |
1989-07-04 |
Cedars Sinai Medical Center |
Heat treatment of Factor VIII
|
US4456590B2
(en)
*
|
1981-11-02 |
1989-05-30 |
|
Heat treatment of lyphilized blood clotting factor viii concentrate
|
US4556558A
(en)
*
|
1982-05-13 |
1985-12-03 |
Cedars-Sinai Medical Center |
Treatment of factor VIII concentrate to minimize the affect of undesirable microorganisms
|
DE3230849A1
(de)
*
|
1982-08-19 |
1984-02-23 |
Behringwerke Ag, 3550 Marburg |
Pasteurisiertes human-fibrinogen (hf) und verfahren zu dessen herstellung
|
DE3237512A1
(de)
*
|
1982-10-09 |
1984-04-12 |
Behringwerke Ag, 3550 Marburg |
Verfahren zur pasteurisierung von antihaemophilem kryopraezipitat (ahk) und danach hergestelltes antihaemophiles kryopraezipitat
|
US4470968A
(en)
*
|
1983-01-13 |
1984-09-11 |
Miles Laboratories, Inc. |
Pasteurized therapeutically active blood coagulation factor concentrates
|
JPS59134730A
(ja)
*
|
1983-01-20 |
1984-08-02 |
Green Cross Corp:The |
血液凝固第8因子の加熱処理法
|
EP0148843B2
(en)
*
|
1983-03-21 |
1994-05-04 |
Novo Nordisk A/S |
A concentrate of the antihemophilic factor viii and a process for producing it
|
AT376881B
(de)
*
|
1983-05-02 |
1985-01-10 |
Immuno Ag |
Verfahren zur inaktivierung von vermehrungsfaehigen krankheitserregern
|
EP0124506B1
(de)
*
|
1983-05-02 |
1988-08-17 |
IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte |
Verfahren zur Inaktivierung von vermehrungsfähigen Krankheitserregern
|
HUT40311A
(en)
*
|
1983-06-03 |
1986-12-28 |
Kiskunhalasi Aag |
Process for producing protein concentrates, blood-curd and nutriments from blood and its elements
|
DE3330770A1
(de)
*
|
1983-08-26 |
1985-03-14 |
Behringwerke Ag, 3550 Marburg |
Verfahren zur pasteurisierung von humanplasma
|
JPS6054287B2
(ja)
*
|
1983-10-19 |
1985-11-29 |
株式会社ミドリ十字 |
血漿蛋白の加熱処理方法
|
US4490361A
(en)
*
|
1983-12-02 |
1984-12-25 |
Alpha Therapeutic Corporation |
Virus inactivating heat treatment of plasma fractions
|
AT389815B
(de)
*
|
1984-03-09 |
1990-02-12 |
Immuno Ag |
Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
|
US5281579A
(en)
*
|
1984-03-23 |
1994-01-25 |
Baxter International Inc. |
Purified virus-free hemoglobin solutions and method for making same
|
US5043428A
(en)
*
|
1984-08-31 |
1991-08-27 |
Behringwerke Aktiengesellschaft |
Pasteurized, isoagglutinin-free factor VIII preparation and a process for its production
|
AT390001B
(de)
*
|
1984-09-28 |
1990-03-12 |
Immuno Ag |
Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
|
DE3602688A1
(de)
*
|
1986-01-30 |
1987-08-06 |
Behringwerke Ag |
Verfahren zur gewinnung und herstellung eines pasteurisierten praeparates von (alpha)(pfeil abwaerts)2(pfeil abwaerts)-antiplasmin
|
DE3621371A1
(de)
*
|
1986-03-12 |
1987-09-17 |
Behringwerke Ag |
Gentechnische herstellung von faktor xiiia
|
JPH0725696B2
(ja)
*
|
1986-05-29 |
1995-03-22 |
株式会社ミドリ十字 |
プラスミノ−ゲンの安定化方法
|
DE3622642A1
(de)
*
|
1986-07-05 |
1988-01-14 |
Behringwerke Ag |
Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung
|
CA1310267C
(en)
*
|
1986-07-09 |
1992-11-17 |
Yutaka Hirao |
Process for heat treating chemically unmodified _-globulin
|
US4749783A
(en)
*
|
1986-07-11 |
1988-06-07 |
Miles Laboratories, Inc. |
Viral inactivation and purification of active proteins
|
DE3625090A1
(de)
*
|
1986-07-24 |
1988-01-28 |
Behringwerke Ag |
Mittel zur therapie faktor viii-resistenter haemophilie a und verfahren zu seiner herstellung
|
AT391808B
(de)
*
|
1986-11-03 |
1990-12-10 |
Immuno Ag |
Verfahren zur herstellung einer faktor viii (ahf)-haeltigen fraktion
|
JPS63243032A
(ja)
*
|
1987-03-27 |
1988-10-07 |
Green Cross Corp:The |
トロンビンの加熱処理方法
|
US4876241A
(en)
*
|
1987-05-22 |
1989-10-24 |
Armour Pharmaceutical Company |
Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
|
WO1989001512A1
(en)
*
|
1987-08-17 |
1989-02-23 |
The Liposome Company, Inc. |
A sponge enzyme having transglutaminase-like activity
|
DK18288D0
(da)
*
|
1988-01-15 |
1988-01-15 |
Nordisk Gentofte |
Fremgangsmaade til pasteurisering af vandige oploesninger af faktor viii
|
US5763394A
(en)
*
|
1988-04-15 |
1998-06-09 |
Genentech, Inc. |
Human growth hormone aqueous formulation
|
US5096885A
(en)
*
|
1988-04-15 |
1992-03-17 |
Genentech, Inc. |
Human growth hormone formulation
|
US5981485A
(en)
*
|
1997-07-14 |
1999-11-09 |
Genentech, Inc. |
Human growth hormone aqueous formulation
|
AU2684488A
(en)
*
|
1988-06-27 |
1990-01-04 |
Carter-Wallace, Inc. |
Test device and method for colored particle immunoassay
|
JPH0341033A
(ja)
*
|
1989-07-07 |
1991-02-21 |
Kyowa Hakko Kogyo Co Ltd |
安定なモチリン類含有製剤
|
FR2650508A1
(fr)
*
|
1989-08-01 |
1991-02-08 |
Fondation Nale Transfusion San |
Colle pasteurisee pour reunir des tissus humain ou animal
|
DE3926034C3
(de)
*
|
1989-08-07 |
1996-11-21 |
Behringwerke Ag |
Verfahren zur Herstellung eines stabilen Faktors VIII
|
DE4001451A1
(de)
*
|
1990-01-19 |
1991-08-01 |
Octapharma Ag |
Stabile injizierbare loesungen von faktor viii und faktor ix
|
JPH03240738A
(ja)
*
|
1990-02-20 |
1991-10-28 |
Hoechst Japan Ltd |
糖尿病性壊疽治療剤
|
JPH0813750B2
(ja)
*
|
1990-03-01 |
1996-02-14 |
持田製薬株式会社 |
経口用トロンビン製剤
|
FR2664165B1
(fr)
|
1990-07-03 |
1992-10-16 |
Lille Transfusion Sanguine |
Composition pour stabiliser le plasma sanguin en cours de pasteurisation.
|
US5314695A
(en)
†
|
1990-11-13 |
1994-05-24 |
Corvas International, Inc. |
Tissue factor based prothrombin time reagent
|
AT402891B
(de)
*
|
1991-06-20 |
1997-09-25 |
Immuno Ag |
Verfahren zur herstellung eines inaktivierten blutproduktes
|
US5792835A
(en)
*
|
1991-09-05 |
1998-08-11 |
Baxter International Inc. |
Method of preparing a topical fibrinogen complex
|
AT399818B
(de)
*
|
1992-04-24 |
1995-07-25 |
Immuno Ag |
Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
|
WO1994013329A1
(de)
*
|
1992-12-16 |
1994-06-23 |
Immuno Aktiengesellschaft |
Verfahren zur herstellung eines virussicheren biologischen präparates
|
RU2143889C1
(ru)
*
|
1993-02-23 |
2000-01-10 |
Генентек, Инк. |
Способ стабилизации полипептида, способы получения композиций полипептида и композиции
|
US5330974A
(en)
*
|
1993-03-01 |
1994-07-19 |
Fibratek, Inc. |
Therapeutic fibrinogen compositions
|
JP3711561B2
(ja)
*
|
1993-04-05 |
2005-11-02 |
三菱ウェルファーマ株式会社 |
アンチトロンビン−▲iii▼液状製剤およびその安定化方法
|
DE4320294A1
(de)
*
|
1993-06-18 |
1994-12-22 |
Immuno Ag |
Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
|
DE4325872C1
(de)
*
|
1993-08-02 |
1994-08-04 |
Immuno Ag |
Virusinaktivierte Faktor Xa-Präparation
|
AT402788B
(de)
*
|
1993-08-03 |
1997-08-25 |
Immuno Ag |
Virussichere blutgerinnungsfaktor xiii-präparation
|
DE69512416T3
(de)
*
|
1994-07-14 |
2011-12-15 |
Croix Rouge De Belgique |
Fibrinogenkonzentrate aus blutplasma, verfahren und anlage für ihre herstellung
|
US5580856A
(en)
*
|
1994-07-15 |
1996-12-03 |
Prestrelski; Steven J. |
Formulation of a reconstituted protein, and method and kit for the production thereof
|
US6399296B1
(en)
*
|
1994-07-20 |
2002-06-04 |
The General Hospital Corporation |
Interaction trap systems for detecting protein interactions
|
WO1996011264A1
(fr)
*
|
1994-10-11 |
1996-04-18 |
Ajinomoto Co., Inc. |
Transglutaminase stabilisee et preparation enzymatique contenant cette transglutaminase
|
DE19508192A1
(de)
*
|
1995-03-09 |
1996-09-12 |
Behringwerke Ag |
Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung
|
SE9501189D0
(sv)
*
|
1995-03-31 |
1995-03-31 |
Pharmacia Ab |
Protein formulation
|
JPH08333277A
(ja)
*
|
1995-06-05 |
1996-12-17 |
Hoechst Japan Ltd |
ヒト血液凝固第xiii因子の安定化された水性液製剤
|
EP1842561A1
(fr)
|
1995-07-14 |
2007-10-10 |
CAF - DCF cvba - scrl |
Procédé et installation d'inactivation UV de virus dans des produits sanguins
|
US5733884A
(en)
|
1995-11-07 |
1998-03-31 |
Nestec Ltd. |
Enteral formulation designed for optimized wound healing
|
DE69733664T3
(de)
|
1996-04-19 |
2011-04-14 |
Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles |
Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen
|
US5989593A
(en)
*
|
1996-11-20 |
1999-11-23 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Method for producing antithrombin-III, method for purifying it, and preparation containing it
|
GB9711927D0
(en)
*
|
1997-06-09 |
1997-08-06 |
Bristol Myers Squibb Co |
Compositions useful as fibrin sealants
|
AUPO871997A0
(en)
*
|
1997-08-25 |
1997-09-18 |
Csl Limited |
Dried biologically or therapeutically active preparations
|
AT407484B
(de)
*
|
1997-11-12 |
2001-03-26 |
Bio Prod & Bio Eng Ag |
Arzneimittel zur förderung der wundheilung
|
WO1999055310A1
(en)
|
1998-04-27 |
1999-11-04 |
Altus Biologics Inc. |
Stabilized protein crystals, formulations containing them and methods of making them
|
CN102161984B
(zh)
|
1998-08-06 |
2016-06-01 |
山景药品公司 |
分离四聚体尿酸氧化酶的方法
|
DE19856443A1
(de)
*
|
1998-12-08 |
2000-06-21 |
Centeon Pharma Gmbh |
Stabilisiertes Antithrombin III-Präparat
|
CZ307715B6
(cs)
|
1999-02-22 |
2019-03-06 |
University Of Connecticut |
Způsob lyofilizace vodné farmaceutické formulace faktoru VIII prosté albuminu
|
US6733985B1
(en)
*
|
1999-05-19 |
2004-05-11 |
International Technidyne Corporation |
Preparation of stable liquid and dried synthetic prothrombin time reagents
|
US6586574B1
(en)
*
|
1999-08-17 |
2003-07-01 |
Nn A/S |
Stabilization of freeze-dried cake
|
AU781678C
(en)
|
1999-11-18 |
2005-12-22 |
Ischemix, Inc. |
Compositions and methods for counteracting effects of reactive oxygen species and free radicals
|
US6890896B1
(en)
|
1999-11-18 |
2005-05-10 |
Ceremedix, Inc. |
Compositions and methods for counteracting effects of reactive oxygen species and free radicals
|
JP4778181B2
(ja)
|
2000-01-28 |
2011-09-21 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
アセチル−アミジニオフェニルアラニル−シクロヘキシルグリシル−ピリジニオアラニンアミドの製造方法
|
DE10012732A1
(de)
*
|
2000-03-18 |
2001-09-20 |
Aventis Behring Gmbh |
Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
|
AU2001259111B2
(en)
|
2000-04-19 |
2005-12-08 |
Durect Corporation |
Sustained release formulations comprising growth hormone
|
DE10022092A1
(de)
|
2000-05-08 |
2001-11-15 |
Aventis Behring Gmbh |
Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
|
US20020176796A1
(en)
*
|
2000-06-20 |
2002-11-28 |
Purepulse Technologies, Inc. |
Inactivation of microbes in biological fluids
|
JP2002112765A
(ja)
*
|
2000-08-01 |
2002-04-16 |
Nihon Pharmaceutical Co Ltd |
ウイルス不活化法
|
US20020146409A1
(en)
*
|
2001-01-30 |
2002-10-10 |
Herring Steven W. |
Methods for stabilizing lyophilized blood proteins
|
JP4724354B2
(ja)
*
|
2001-02-23 |
2011-07-13 |
ジェネンテック, インコーポレイテッド |
注射用の崩壊性ポリマー
|
EP1401862A4
(en)
*
|
2001-05-17 |
2004-12-15 |
Ceremedix Inc |
PEPTIDE COMPOUNDS AGAINST OXYGENIC SUBSTANCES AND FREE RADICALS
|
US7318931B2
(en)
*
|
2001-06-21 |
2008-01-15 |
Genentech, Inc. |
Sustained release formulation
|
UY27373A1
(es)
*
|
2001-07-09 |
2003-02-28 |
Schering Ag |
Formulaciones de interferón beta-humano
|
KR20040065278A
(ko)
*
|
2001-12-21 |
2004-07-21 |
노보 노르디스크 에이/에스 |
변경된 인자 ⅶ 폴리펩티드의 액체 조성물
|
BR0215218A
(pt)
*
|
2001-12-21 |
2004-11-16 |
Novo Nordisk As |
Composição aquosa lìquida, método para a preparação da mesma, uso de uma composição, e, métodos para a inibição da coagulação do sangue em um indivìduo, e inibição de reações mediadas pelo fator de tecido em um indivìduo
|
AU2002351756A1
(en)
|
2001-12-21 |
2003-07-15 |
Novo Nordisk Health Care Ag |
Liquid composition of factor vii polypeptides
|
US20040009918A1
(en)
*
|
2002-05-03 |
2004-01-15 |
Hanne Nedergaard |
Stabilised solid compositions of modified factor VII
|
EP2283856B1
(en)
|
2002-06-21 |
2017-09-20 |
Novo Nordisk Health Care AG |
Stabilised solid compositions of factor VIIa polypeptides
|
AT501088A2
(de)
*
|
2002-12-18 |
2006-06-15 |
Bio Prod & Bio Eng Ag |
Stabile therapeutische proteine
|
WO2004082708A2
(en)
*
|
2003-03-18 |
2004-09-30 |
Novo Nordisk Health Care Ag |
Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
|
US7897734B2
(en)
*
|
2003-03-26 |
2011-03-01 |
Novo Nordisk Healthcare Ag |
Method for the production of proteins
|
US20040229778A1
(en)
*
|
2003-05-13 |
2004-11-18 |
Elmaleh David R. |
Pharmaceutical compositions of antithrombin III for the treatment of retroviral diseases
|
US7498130B2
(en)
*
|
2003-05-13 |
2009-03-03 |
Massachusetts General Hospital |
Method of reducing viral load
|
MXPA05012476A
(es)
*
|
2003-05-23 |
2006-02-22 |
Novo Nordisk Healthcare Ag |
Estabilizacion de proteina en solucion.
|
WO2004112828A1
(en)
*
|
2003-06-25 |
2004-12-29 |
Novo Nordisk Health Care Ag |
Liquid composition of factor vii polypeptides
|
DE602004023848D1
(de)
*
|
2003-07-01 |
2009-12-10 |
Novo Nordisk Healthcare Ag |
Von factor vii polypeptiden
|
BRPI0413518A
(pt)
|
2003-08-14 |
2006-10-10 |
Novo Nordisk Healthcare Ag |
composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético
|
TR201809670T4
(tr)
*
|
2003-12-19 |
2018-07-23 |
Novo Nordisk Healthcare Ag |
Faktör VII polipeptitlerinin stabilize edilmiş kompozisyonları.
|
KR100624013B1
(ko)
*
|
2004-06-25 |
2006-09-19 |
주식회사 녹십자홀딩스 |
동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
|
US8148123B2
(en)
|
2005-04-11 |
2012-04-03 |
Savient Pharmaceuticals, Inc. |
Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
|
WO2006110761A2
(en)
|
2005-04-11 |
2006-10-19 |
Savient Pharmaceuticals, Inc. |
A variant form of urate oxidase and use thereof
|
HUE052976T2
(hu)
|
2005-04-11 |
2021-06-28 |
Horizon Pharma Rheumatology Llc |
Urát-oxidáz variáns formái és azok alkalmazása
|
US20080159976A1
(en)
*
|
2005-04-11 |
2008-07-03 |
Jacob Hartman |
Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
|
US20090081122A1
(en)
*
|
2005-05-23 |
2009-03-26 |
Universite De Geneve |
Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
|
JP5058160B2
(ja)
*
|
2005-06-30 |
2012-10-24 |
ジーイー・ヘルスケア・バイオサイエンス・コーポレイション |
遺伝子発現の検出方法
|
PL2013225T3
(pl)
*
|
2006-04-12 |
2015-06-30 |
Crealta Pharmaceuticals Llc |
Oczyszczanie białek z zastosowaniem kationowego środka powierzchniowo czynnego
|
KR101897534B1
(ko)
*
|
2008-04-21 |
2018-09-12 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
건조한 트랜스글루타미나제 조성물
|
AU2009312235B2
(en)
|
2008-11-04 |
2014-01-16 |
Aska Pharmaceutical Co., Ltd. |
Aqueous composition containing follicle-stimulating hormone
|
TR201900207T4
(tr)
|
2008-11-07 |
2019-02-21 |
Baxalta GmbH |
Faktör VIII Formülasyonları
|
MX347903B
(es)
|
2009-06-25 |
2017-05-18 |
Crealta Pharmaceuticals Llc |
Metodos y equipos para predecir el riesgo de reaccion a la infusion y perdida de respuesta mediada por anticuerpos al supervisar el acido urico en suero durante una terapia con uricasa conjugada con peg.
|
RU2739078C2
(ru)
|
2010-04-27 |
2020-12-21 |
ЭсСиАйЭл Текнолоджи ГмбХ |
Стабильные водные композиции белка MIA/CD-RAP
|
IL213864A0
(en)
|
2011-06-30 |
2011-08-31 |
Omrix Biopharmaceuticals Ltd |
Method for removing a lytic enzyme from a heterogeneous mixture
|
US9833410B2
(en)
|
2012-10-31 |
2017-12-05 |
Takeda Gmbh |
Lyophilized formulation comprising GM-CSF neutralizing compound
|
AR093297A1
(es)
|
2012-10-31 |
2015-05-27 |
Amgen Res (Munich) Gmbh |
Formulacion liquida que comprende un compuesto neutralizante de gm-csf
|
EP3889178A1
(en)
|
2013-08-30 |
2021-10-06 |
Takeda GmbH |
Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
|
RU2556804C2
(ru)
*
|
2013-12-17 |
2015-07-20 |
Федеральное государственное бюджетное учреждение Гематологический научный центр Министерства здравоохранения РФ |
Способ получения концентрата фибриногена
|
IL231230A0
(en)
|
2014-02-27 |
2014-08-31 |
Omrix Biopharmaceuticals Ltd |
Fibrinogen preparation
|
KR102385802B1
(ko)
|
2014-05-07 |
2022-04-13 |
다케다 야쿠힝 고교 가부시키가이샤 |
Gm-csf 중화 화합물을 포함하는 액체 제제
|
AU2015367185B2
(en)
|
2014-12-19 |
2021-05-27 |
Prometic Bio Therapeutics, Inc. |
Pharmaceutical composition comprising plasminogen and uses thereof
|
IL247821A0
(en)
|
2016-09-14 |
2017-01-31 |
Omrix Biopharmaceuticals Ltd |
Adhesive preparations and their use
|
WO2019182123A1
(ja)
*
|
2018-03-23 |
2019-09-26 |
味の素株式会社 |
トランスグルタミナーゼを含有する液体製剤
|
KR20200144120A
(ko)
*
|
2018-04-16 |
2020-12-28 |
메르크 파텐트 게엠베하 |
열 안정성을 개선하기 위한 단백질 제제에 대한 첨가제
|
IL263679A
(en)
|
2018-12-12 |
2019-03-31 |
Omrix Biopharmaceuticals Ltd |
Kits, methods, and ingredients for preventing tissue adhesion
|
WO2020121290A1
(en)
|
2018-12-12 |
2020-06-18 |
Omrix Biopharmaceuticals Ltd. |
High concentrated protein compositions for preventing tissue adhesion
|
WO2023119277A1
(en)
|
2021-12-21 |
2023-06-29 |
Omrix Biopharmaceuticals Ltd. |
Highly soluble fibrinogen compositions
|